Our Community

Developing Innovative Therapies
to Change Patient’s Lives for the Better

hand in hand

Patient Advocacy

We understand the importance of listening to the voices of patients living with life-threatening diseases. Our relationship with patient advocacy groups helps us gain a deeper understanding of the diseases we explore. Their experience inspires us to leave no stone unturned in our quest to develop safe and effective therapies.

We work closely with patient advocacy groups to support our common goal of improving the lives of patients and caregivers impacted by serious diseases. Find additional information and resources for Friedreich’s ataxia, Alport syndrome, and other rare diseases through these patient organizations.

Chronic Kidney Disease
AAKP Logo
ASF Logo
NKF Logo
Ataxia
FARA Logo
NAF Logo

Clinical Trials

To advance patient care, investigational drugs must progress through rigorous trials in multiple clinical studies to demonstrate safety and efficacy. These studies, referred to as clinical trials, are regulated by the U.S. Food and Drug Administration (FDA) and similar regulatory agencies worldwide including the European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

To learn about all our ongoing clinical trials, please check our pipeline page. Currently, Reata is conducting the following clinical trials:

  • FALCON pivotal study of bardoxolone methyl in patients with chronic kidney disease (CKD) caused by autosomal dominant polycystic kidney disease (ADPKD)
  • MERLIN Phase 2 study of bardoxolone methyl in patients with CKD at risk for rapid progression

For a full list of ongoing and completed trials, please check Reata’s clinicaltrials.gov page.

clinical trials
Benbrook Lake